These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Practical follow-up of a patient treated with finasteride in screening for prostate cancer]. Villers A Prog Urol; 2008 Apr; 18 Suppl 3():S58-62. PubMed ID: 18455086 [TBL] [Abstract][Full Text] [Related]
23. Effect of finasteride treatment on suburethral prostatic microvessel density in patients with hematuria related to benign prostate hyperplasia. Memis A; Ozden C; Ozdal OL; Guzel O; Han O; Seckin S Urol Int; 2008; 80(2):177-80. PubMed ID: 18362489 [TBL] [Abstract][Full Text] [Related]
24. Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Koivisto PA; Schleutker J; Helin H; Ehren-van Eekelen C; Kallioniemi OP; Trapman J Clin Cancer Res; 1999 Nov; 5(11):3578-82. PubMed ID: 10589774 [TBL] [Abstract][Full Text] [Related]
25. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer. Reed AB; Parekh DJ Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950 [TBL] [Abstract][Full Text] [Related]
26. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. Anwarul Islam AK; Kashem MA; Shameem IA; Kibria SA Bangladesh Med Res Counc Bull; 2005 Aug; 31(2):54-61. PubMed ID: 16967810 [TBL] [Abstract][Full Text] [Related]
27. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia]. Botto H; Lan O; Poulain JE; Comenducci A Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658 [TBL] [Abstract][Full Text] [Related]
28. Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Rubin MA; Allory Y; Molinié V; Leroy X; Faucon H; Vacherot F; Huang W; Kuten A; Salomon L; Rebillard X; Cussenot O; Abbou C; de la Taille A Urology; 2005 Nov; 66(5):930-4. PubMed ID: 16286097 [TBL] [Abstract][Full Text] [Related]
29. [Comparative evaluation of the effectiveness and safety of combined drug therapy of patients with benign prostatic hyperplasia with finasteride and alfuzozine]. Loran OB; Pushkar' DIu; Rasner PI Urologiia; 2002; (1):19-22. PubMed ID: 11877966 [TBL] [Abstract][Full Text] [Related]
30. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction. Rittmaster RS Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794 [TBL] [Abstract][Full Text] [Related]
33. The REDUCE trial: chemoprevention in prostate cancer using a dual 5alpha-reductase inhibitor, dutasteride. Musquera M; Fleshner NE; Finelli A; Zlotta AR Expert Rev Anticancer Ther; 2008 Jul; 8(7):1073-9. PubMed ID: 18588452 [TBL] [Abstract][Full Text] [Related]
34. Therapeutic hotline. Treatment of androgenic alopecia with finasteride may result in a high grade prostate cancer in patients: fact or fiction? Lynn R; Krunic A Dermatol Ther; 2010; 23(5):544-6. PubMed ID: 20868409 [TBL] [Abstract][Full Text] [Related]
35. [Influence of dihydrotestosterone deficit on treatment of prostatic diseases regarding to contemporary methods of prostatic hypertrophy treatments]. Laszczyńska M; Chorzepa-Nowicka K; Wylot M; Piasecka M; Gaczarzewicz D Pol Merkur Lekarski; 2008 Dec; 25(150):528-30. PubMed ID: 19205388 [TBL] [Abstract][Full Text] [Related]
36. Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study. Murtola TJ; Tammela TL; Määttänen L; Hakama M; Auvinen A Eur J Cancer; 2007 Mar; 43(4):775-81. PubMed ID: 17251005 [TBL] [Abstract][Full Text] [Related]
37. Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. Sutton MT; Yingling M; Vyas A; Atiemo H; Borkowski A; Jacobs SC; Kyprianou N Prostate; 2006 Aug; 66(11):1194-202. PubMed ID: 16652387 [TBL] [Abstract][Full Text] [Related]
38. [Finasteride in prolonged therapy of patients with benign prostatic hyperplasia]. Mazo EB Urologiia; 2001; (3):20-2. PubMed ID: 11505535 [TBL] [Abstract][Full Text] [Related]
39. Pharmacological approaches to reducing the risk of prostate cancer. Rittmaster RS; Fleshner NE; Thompson IM Eur Urol; 2009 May; 55(5):1064-73. PubMed ID: 19200641 [TBL] [Abstract][Full Text] [Related]
40. Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. Eggener SE; Stern JA; Jain PM; Oram S; Ai J; Cai X; Roehl KA; Wang Z Prostate; 2006 Apr; 66(5):495-502. PubMed ID: 16372330 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]